Background New-onset diabetes (NOD) increases the risk of pancreatic cancer. Previous studies have mainly focused on the ...

Background Fistulising perianal Crohn’s disease (CD) remains a debilitating condition, with few randomised controlled trials ...

Background Pancreatic ductal adenocarcinoma (PDAC) is largely refractory to immune checkpoint blockade, owing to its ...

We read with great interest the recent study by Lau et al , who reported distinct intrahepatic hepatitis B virus (HBV) ...

Background Endoscopic submucosal dissection (ESD) enables en bloc resection of early gastrointestinal cancers and provides ...

We read with great interest the study by Lenti et al published in Gut , providing the first large-scale assessment of clinical features and gastric neoplastic risk in autoimmune gastritis (AIG).1 ...

Background The classification of IBD into ulcerative colitis (UC) and Crohn’s disease (CD) is based on clinicopathological criteria established in the 20th century. Whether this binary reflects ...

Clinical trials in IBD face difficulties of escalating complexity, high costs and challenges in recruitment. Digital twins are virtual, data-driven replicas of individual patients that model disease ...

Background CDH1 is commonly mutated in sporadic diffuse gastric cancer (DGC) and germline CDH1 mutations underlie most cases of the cancer syndrome hereditary DGC. Objective We aimed to develop mouse ...

Background Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy characterised by remarkable cellular heterogeneity, which emerges early from the interplay of oncogenic KRAS ...

Background HBV surface antigen (HBsAg) seroconversion indicates the clearance of HBV in patients with chronic HBV infection. Objective We aimed to investigate the predictive value of HBV RNA and HBV ...

We read with great interest the review by Suo et al published in Gut recently, ‘Spatial single-cell omics: new insights into liver diseases’.1 This very well-written and comprehensive review ...